News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Thomas Decker

Articles by Thomas Decker

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

ByRadhika Appaya,Erika P. Hamilton, MD,Thomas Decker,Hope S. Rugo, MD,Maria Fernandez Abad,Kevin Kalinsky, MD, MS,Qiang Liu,Mariya Rozenblit, MD,Barbara Radecka,Seock-Ah Im,Frances Visco,Alejandro Perez,Yogesh Chattar,Murat Akdere,Vaidyanathan Ganapathy,Sorcha Waters,Joyce O’Shaughnessy, MD

June 27th 2025

19 Efficacy, Safety, and Quality of Life With Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

19 Efficacy, Safety, and Quality of Life With Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

ByLowell Hart,Seock-Ah Im,Sara M. Tolaney, MD, MPH,Mario Campone,Timothy Pluard,Berta Sousa,Gilles Freyer,Thomas Decker,Kevin Kalinsky, MD, MS,Astrid Thuerigen,Melissa Gao,Huilin Hu,Sherko Kümmel

August 9th 2024

Latest Updated Articles

Trending on CancerNetwork

Teclistamab Combo Approval is ‘Excellent’ for R/R Multiple Myeloma

Isatuximab Regimen Improves MRD Negativity in Transplant-Eligible NDMM

Lu-PSMA-617/Pembrolizumab Shows Early Efficacy in Metastatic CRPC

Navigating ADC Sequencing Beyond the First Line in Breast Cancer

Navigating the 2026 ASCO Guideline Update on Managing Thyroid Cancer